Regulatory FDA greenlights Roche’s biomarker blood test for Alzheimer’s PharmaphorumRoche has won US FDA clearance for a blood test that could move Alzheimer's biomarker testing further into primary care.NeuroscienceRead full story pharminent August 25, 2026 (Last updated: August 25, 2026) Pharmaphorum Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care. Neuroscience Read full story Post navigation Previous: FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trialNext: Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail Related Stories Regulatory FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial pharminent August 25, 2026 Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026
